证券代码：300358 证券简称：楚天科技 公告编号：2023-065 号 楚天科技股份有限公司 关于调整向不特定对象发行可转换公司债券方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）分别于 2023 年 3 月 20 日、2023 年 5 月 22 日、2023 年 6 月 8 日召开第五届董事会第十一次会议、第五届董事会第十 三次会议及 2023 年第一次临时股东大会，审议通过了公司向不特定对象发行可转换 公司债券的相关议案。 为了本次公司向不特定对象发行可转换公司债券（以下简称"可转债"）工作的 顺利进行，并结合公司实际情况，公司于 2023 年 8 月 9 日召开第五届董事会第十五 次会议，审议通过了《关于调整公司向不特定对象发行可转换公司债券方案的议案》 等相关议案，将本次可转债的发行规模调整为不超过人民币 100,000.00 万元（含 100,000.00 万元），并相应调整募集资金具体用途的规模，本次发行方案的其他条款 不变。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 ...

证券代码：300358 证券简称：楚天科技 公告编号：2023-066 号 楚天科技股份有限公司 关于向不特定对象发行可转换公司债券摊薄即期回报 及填补措施和相关主体承诺的公告（修订稿） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本公告中关于楚天科技股份有限公司（以下简称"公司"）本次向不特定对 象发行可转换公司债券（以下简称"可转债"）发行后其主要财务指标的分析、描述 均不代表公司对未来经营情况及趋势的判断，不构成公司的盈利预测，为应对即期回 报被摊薄风险而制定的填补回报具体措施不等于对公司未来利润做出保证，投资者不 应据此进行投资决策，投资者据此进行投资决策造成损失的，公司不承担赔偿责任。 敬请广大投资者注意。 2、公司向不特定对象发行可转债相关事项已经公司第五届董事会第十五次会议、 第五届监事会第十四次会议及股东大会审议通过，尚需深圳证券交易所（以下简称"深 交所"）审核通过和中国证券监督管理委员会（以下简称"证监会"）同意注册。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作的意 见》《国务院关于进一步促进资本 ...

关于楚天科技股份有限公司 申请向不特定对象发行可转换公司债券 审核问询函的回复报告 保荐机构（主承销商） （成都市青羊区东城根上街 95 号） 二〇二三年八月 楚天科技股份有限公司 审核问询函的回复报告 关于楚天科技股份有限公司 申请向不特定对象发行可转换公司债券的审核问询函的 回复报告 深圳证券交易所： 贵所于 2023 年 7 月 19 日出具的《关于楚天科技股份有限公司申请向不特定 对象发行可转换公司债券的审核问询函》（审核函[2023] 020116 号）（以下简称 "审核问询函"）已收悉。楚天科技股份有限公司（以下简称"楚天科技"、"公 司"、"发行人"）与国金证券股份有限公司（以下简称"保荐机构"、"保荐 人"或"国金证券"）、湖南启元律师事务所（以下简称"发行人律师"）、中 审众环会计师事务所（特殊普通合伙）（以下简称"发行人会计师"或"会计师"） 等相关方对审核问询函所列问题进行了逐项核查落实和书面说明，并对楚天科技 股份有限公司申请文件有关内容进行了必要的修改、补充说明或更新，现回复如 下，请予审核。 如无特别说明，本回复所用释义与《《楚天科技股份有限公司向不特定对象 发行可转换公司债券募集 ...

证券代码：300358 证券简称：楚天科技 公告编号：2023-061 号 楚天科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）第五届董事会第十五次会议于 2023 年 8 月 9 日以通讯方式召开。会议通知于 2023 年 8 月 3 日以电子邮件方式送达给全 体董事。本次会议由公司董事长唐岳先生召集并主持，应出席董事 11 人，实际出席 董事 11 人，符合《中华人民共和国公司法》和《楚天科技股份有限公司章程》的有 关规定，公司监事列席会议。本次会议采用记名投票方式，审议并通过了如下议案： 一、逐项审议通过《关于调整公司向不特定对象发行可转换公司债券方案的议 案》 为了本次公司向不特定对象发行可转换公司债券（以下简称"可转债"）工作的 顺利进行，根据相关法律法规及公司目前的财务状况和投资计划，本次可转债发行规 模将从不超过人民币 110,000.00 万元（含 110,000.00 万元）减至不超过人民币 100,000.00 万元（含 100,000.00 万元） ...

楚天科技股份有限公司 投资者关系活动记录表 编号：2023-004 | 调研活动类别 | 特定对象调研 □分析师会议 | | --- | --- | | | 媒体采访  业绩说明会 | | | □新闻发布会 □路演活动 | | | 现场参观 □其他 | | 参与单位名称及 人员姓名 | 通过线上参与楚天科技 2022 年度网上业绩说明会的投资者 | | 时间 | 2023 年 4 月 27 日 15:00-17:00 | | 地点 | 上海证券报·中国证券网 https://roadshow.cnstock.com/ | | 上市公司 | 董事长兼总裁：唐岳 副总裁兼董事会秘书：周飞跃 | | 接待人员姓名 | 副总裁兼财务总监：肖云红 | | | 独立董事：张早平 | | | 公司于 2023 年 4 月 27 日（星期四）下午 15:00-17:00 在上海 | | | 证券报·中国证券网 https://roadshow.cnstock.com/，举办 | | | 2022 年度业绩说明会，本次业绩说明会采用网络远程的方式举 | | | 行，业绩说明会问答环节主要内容如下： | | | 1、请问 ...

Business Strategy and Market Expansion - The company aims to become a leading global pharmaceutical equipment enterprise by 2030, targeting sales of approximately 20 billion RMB[12]. - In 2023, the company plans to enhance market expansion and operational management, focusing on increasing order volume and contract amounts[13]. - The company has established over ten sales and service outlets in international markets, with plans to further expand in key international markets in 2023[16]. - The company will continue to strengthen its domestic market share while expanding into international markets, particularly in Asia, the Middle East, Africa, and South America[13]. - The company aims to accelerate the development and market expansion of new products, including automatic cell production equipment and special formulations[13]. - The company is expanding its market presence in Southeast Asia, with plans to enter two new countries by the end of 2023[64]. - The company plans to expand its market presence through new product development and technological advancements, focusing on the pharmaceutical equipment sector[85]. - Chutian Technology is actively pursuing mergers and acquisitions to enhance its competitive edge and market share in the biotechnology industry[85]. Financial Performance - Chu Tian Technology reported a revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[64]. - The company achieved a net profit of 150 million RMB in 2022, up 10% compared to the previous year[64]. - The company has set a revenue target of 1.5 billion RMB for 2023, which would represent a growth of 25% year-over-year[64]. - The total revenue for Chutian Technology Co., Ltd. in 2022 was 1,235.61 million CNY, reflecting a significant growth compared to the previous year[89]. - The company has set ambitious performance guidance for 2023, aiming for a revenue increase of at least 15% year-over-year[85]. Research and Development - The company is committed to increasing R&D investment to maintain its leading position in sterile filling and packaging solutions[16]. - The company is investing 100 million RMB in R&D for new technologies in automation and robotics[64]. - The company has implemented a three-year restricted stock incentive plan for core employees to attract and retain talent, ensuring sustainable business development[120]. - The company is investing heavily in research and development, allocating approximately 10% of its revenue to innovation initiatives[85]. Governance and Compliance - The company emphasizes compliance with laws and regulations to enhance corporate governance and internal control systems[29]. - The company maintains an independent operational structure, ensuring no interference from the controlling shareholder in business activities[31]. - The board of directors operates independently and adheres to legal requirements for governance and decision-making processes[32]. - The supervisory board actively monitors major transactions and compliance of directors and senior management, safeguarding shareholder interests[34]. - The company has established a transparent performance evaluation and incentive mechanism for its directors, supervisors, and senior management, ensuring compliance with relevant laws and regulations[39]. - The company has no significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[42]. - The company is committed to ensuring compliance with regulatory requirements and has taken steps to enhance corporate governance practices[107]. Risk Management - The company faces risks related to potential underperformance in high-end import substitution and rising raw material costs[18]. - The company faces a risk of significant impairment of goodwill, technology, patents, brand, and customer relationships if external factors such as macroeconomic conditions and market environments change drastically[19]. - The company's 2030 strategic goals may not be met if there are major changes in the industry or market conditions, which could impact overall performance[21]. - The company has established a risk internal control management system to supervise and evaluate internal control management[138]. Employee and Talent Management - The company reported a total of 3,000 employees at the end of the reporting period, with a focus on maintaining a skilled workforce[110]. - The company conducted training for 2,738 employees, including 1,328 new employees, achieving a 100% pass rate for pre-job training[121]. - The company has a total of 7,792 employees, with 40 holding doctoral degrees and 304 holding master's degrees[118]. - The company aims to ensure salary compliance and maintain competitive compensation for industry talents, leading to long-term competitiveness[119]. Environmental Commitment - The company has maintained a strong commitment to environmental protection, adhering to various environmental laws and regulations without facing any administrative penalties[156]. - The company has implemented measures to reduce carbon emissions and promote green operations, with no environmental violations reported in 2022[157][160]. - The management team emphasized a focus on sustainability initiatives, aiming for a 30% reduction in carbon emissions by 2025[64]. Shareholder Engagement and Returns - The company plans to implement a three-year dividend return plan for shareholders from 2023 to 2025, which was approved during the annual general meeting[46]. - The company plans to distribute a cash dividend of 1.0 yuan (including tax) for every 10 shares, totaling 57,505,298.4 yuan (including tax) based on a total share capital of 575,052,984 shares as of December 31, 2022[125]. - The company plans to maintain a cash dividend ratio of at least 20% during profit distribution, given its growth stage and significant capital expenditure arrangements[125]. Internal Control and Audit - The company has implemented a comprehensive internal control system covering all business activities and internal management aspects[143]. - The internal control self-evaluation report indicated no major defects in internal control during the reporting period[138]. - The company reported zero significant defects in both financial and non-financial internal controls for the year 2022[148]. - The audit committee held one meeting on April 21, 2022, where it unanimously agreed on the reappointment of the auditing firm[108]. Strategic Partnerships and Collaborations - A new partnership with a leading tech firm was established to co-develop advanced packaging technologies, expected to launch in Q3 2023[64]. - The company has established strategic partnerships with key industry players to facilitate market expansion and technology sharing[85]. Leadership and Management - The company has a diverse leadership team with significant experience in the pharmaceutical and machinery sectors, enhancing its operational capabilities[60]. - The management team includes professionals with extensive backgrounds in engineering and business management, which supports strategic decision-making[61]. - The current board members include Chairman and CEO Tang Yue, who holds 3,379,200 shares, and Executive President Zeng Fanyun, who holds 2,328,800 shares, both with no changes in shareholding during the period[52].

Financial Performance - The company's operating revenue for the current period is ¥1,553,392,936.78, representing a 13.49% increase compared to the same period last year[3] - Net profit attributable to shareholders for the current period is ¥133,378,983.03, a 3.86% increase year-over-year[3] - Net profit for the current period was ¥134,572,400.59, representing a 6.5% increase from ¥126,109,671.27 in the previous period[31] - The total profit for the current period was ¥147,064,715.14, an increase of 7.5% from ¥136,612,669.18 in the last period[31] - The total comprehensive income for the current period was ¥144,762,047.17, compared to ¥103,214,262.13 in the previous period, marking a substantial increase[31] Cash Flow - The net cash flow from operating activities improved by 47.79%, reaching -¥331,395,404.12 compared to -¥634,793,368.16 in the previous year[3] - The net cash flow from operating activities for the current period was -331,395,404.12, an improvement from -634,793,368.16 in the previous period, indicating a reduction in cash outflow[15] - Cash inflow from operating activities totaled 1,643,073,589.40, compared to 1,408,088,107.11 in the previous period, reflecting a year-over-year increase of approximately 16.7%[15] - Cash outflow from operating activities decreased to 1,974,468,993.52 from 2,042,881,475.27, showing a reduction of about 3.3%[15] - The net cash flow from investing activities was -165,221,647.72, an improvement from -239,159,561.23 in the previous period[15] - Cash inflow from investing activities decreased significantly to 57,071,027.65 from 1,028,578,035.06, indicating a decline of approximately 94.5%[15] - Cash outflow from investing activities also decreased to 222,292,675.37 from 1,267,737,596.29, reflecting a reduction of about 82.5%[15] - The net cash flow from financing activities increased to 152,918,110.42 from 109,998,158.76, representing a growth of approximately 39%[17] Assets and Liabilities - The total assets at the end of the current period are ¥10,816,725,455.99, a decrease of 2.09% from the end of the previous year[3] - Total liabilities decreased to 6,360,976,921.31 from 6,751,469,493.90, indicating a reduction of about 5.8%[26] - The total equity increased to 4,455,748,534.68 from 4,296,041,389.28, reflecting an increase of approximately 3.7%[26] - The company's equity attributable to shareholders increased by 3.61% to ¥4,365,776,962.67 compared to the previous year[3] Expenses - Total operating costs amounted to ¥1,394,152,500.76, up 14.2% from ¥1,221,046,192.81 in the prior period[29] - Research and development expenses increased to ¥117,069,572.72, up 22% from ¥96,075,455.10 in the previous period[29] - Financial expenses rose by 635.02% to ¥12,537,900.00, primarily due to increased foreign exchange losses and interest expenses[6] - The company reported a significant increase in financial expenses, which rose to ¥14,512,288.23 from ¥1,974,401.31 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,889[38] - The largest shareholder, Changsha Chutian Investment Group Co., Ltd., holds 38.96% of shares, totaling 224,049,214 shares[38] Government and Other Income - The company received government subsidies amounting to ¥8,573,087.30, which are closely related to its normal business operations[9] - Other comprehensive income after tax was ¥10,189,646.58, a recovery from a loss of ¥22,895,409.14 in the previous period[31] - Investment income decreased by 3.51 million RMB, a decline of 131.53%, primarily due to losses from an associated company and reduced returns from financial products[51] - Asset disposal income increased by 1.67 million RMB, a growth of 2261.58%, due to the disposal of fixed assets by Romaco Tecpharm, S.L.[51] Future Plans - The company plans to issue convertible bonds not exceeding 1.1 billion for projects related to bioengineering and medical equipment, as well as to supplement working capital[19] - The company is undergoing a merger and acquisition review process, with the Shenzhen Stock Exchange confirming that the transaction meets restructuring conditions[13] Miscellaneous - The report confirms that the financial information is true, accurate, and complete[44] - The first quarter report has not been audited[52] - The total number of restricted shares at the beginning of the period was 58,120,691, with no shares released during the reporting period[41] - The company has no other significant non-recurring gains or losses to report[54] - Other equity instrument investments increased by 3 million yuan, a growth of 1337.37%, mainly due to the investment payment for the Changsha Jingji Biomedical Industry Investment Partnership project during the reporting period[55]

证券代码:300358 证券简称:楚天科技 公告编号：2023-026 号 楚天科技股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）已于2023年4月25日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露了《楚天科技2022年年度报告》,公司拟于 2023年4月27日（星期四）15:00-17:00 举行2022年度报告业绩说明会。现将具体情 况公告如下： 为充分尊重投资者、提升交流的针对性，公司就 2022 年度报告业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 27 日(星期四)15:00 前访问 https://company.cnstock.com/wtzj/300358，进入问题征 集专题页面进行提问。 公司将在 2022 年度报告业绩说明会上，在信息披露允许的范围内就投资者关注 的问题进行回答 特此公告。 2、召开地点：上海证券报·中国证券网 https://roadsho ...

Group 1: Industry Trends and Market Dynamics - The pharmaceutical equipment industry is experiencing a slowdown in growth due to the end of GMP certification, with a market contraction expected as a result of policy changes and the transition to a new normal in China's economy [3][4] - Despite the apparent downturn, the pharmaceutical industry maintained a 20% growth rate over the past year, indicating that the absolute market size has not decreased [4] - The Chinese pharmaceutical equipment production remains the largest globally, but the overall technology quality is still at a mid to lower level, suggesting room for improvement and innovation [4] Group 2: Company Strategy and Product Development - The company anticipates that traditional linked line product sales have reached their lowest point, with a return to normalcy expected in approximately three years [5] - Intelligent manufacturing is identified as a key development direction, with specific applications in self-detection and self-correction capabilities for machines [5][6] - The company is focusing on upgrading traditional linked line products, with initial implementations in areas such as ampoule bottles and oral solutions [6] Group 3: Financial Projections and Sales Goals - For 2015, the company aims to maintain traditional linked line product sales while achieving new product sales targets: approximately 70-80 million for liquid preparation systems, 50 million for intelligent post-packaging, and 150 million for intelligent inspection machines [9] - The company plans to achieve a sales target of 20 billion through both organic growth and acquisitions, supported by a significant increase in technical personnel across its research institutes [10] Group 4: Workforce and Talent Management - The company has streamlined its management structure, reducing the number of management personnel while increasing sales and R&D staff, with plans to recruit 50-100 R&D talents annually from top universities [8]